Company | ArkMS Co., Ltd.

Vision

Taking on challenges together, passing on to the next-generation medical care

Together with people who are challenging infinite possibilities of medical care, we will serve as a bridge to deliver credible data and evidence to the present and future generations.

CEO Message

In addition to the increase of medical expenses and changes in systems and regulations, the environment surrounding medical care has changed dramatically in the context of advances in digital transformation in healthcare, with the use of real-world data (RWD) and AI opening up new possibilities.
In the process from development to post-marketing of drugs and medical devices, we are increasingly required to pursue scientific evidence and correctly understand the voices of each and every patient as well as opinions from medical institutions, with a view toward further improving the quality of medical care.

For many years, we have been working with Japanese and overseas pharmaceutical companies as a CRO that works to solve issues in pharmaceutical development. As a member of the Alfresa Group, which is a trusted partner to many medical institutions and pharmaceutical companies, we aim to promote further cooperation with medical institutions and utilization of RWD while supporting with clinical trials and safety information management based on our experience and expertise.

We will continue to be a partner specialists in each area―clinical development, safety, and data science―and will work closely with medical institutions, pharmaceutical companies, and researchers to solve issues together.

Ark Medical Solutions Inc. (ArkMS) connects real medical voices with scientifically supported solid data and will continue to take on challenges as a CRO that supports the next generation of medical care.

President and Representative Director MIZUO Akira

Company Overview

Company Name

Ark Medical Solutions Inc. (abbreviated ArkMS)

Core Businesses

Clinical trial & study / Post-marketing surveillance/ RWE

Established

September 2, 2024

Capital

JPY 300,000,000（Alfresa Holdings Corporation 100% ownership）

President and Representative Director

Akira MIZUO

Director, Member of the Board

Director: Yuichi YAHAGI
Director (Non-resident): Ryota KUBO
Director (Non-resident): Soichi(Sean） NEMOTO

Audit & Supervisory

Takashi SASAKI

Number of Employees

263 (As of April 2026)

Affiliated Organizations / Institutions

Headquarters

Address: 13F Hareza Tower, 1-18-1, Higashi-Ikebukuro Toshima-ku, Tokyo 170-0013 Japan
TEL：+81-03-5979-1001
FAX：+81-03-3590-7111

Osaka Office

Address: JAM-STUDIO 305,GRAND GREEN OSAKA North building JAM BASE 3F 6-38 Ofuka-cho, Kita-ku, Osaka-shi, Osaka 530-0011 Japan

Our History

More More More

1992: Establishment of IBRD JAPAN Co., Ltd.
2000: All shares of IBRD JAPAN Co., Ltd. were transferred to Social Research Institute (renamed INTAGE Inc. in 2001), making it a wholly owned subsidiary.
2003: IBRD JAPAN Co., Ltd. merged with the Medical Solutions Division of INTAGE Inc. and was renamed Asklep Inc.
2004: Launch of EDC solution services in post-marketing surveillance
2008: Concluded a strategic licensing and development agreement with XClinical (Germany) and introduced the EDC system "MARVIN"
2008: Concluded a strategic partnership agreement with an overseas CRO and launched full-scale global operations
2010: Established a local subsidiary in China (ASKLEP CHINA Inc. / 阿思克瑞普医薬諮詢（上海）有限公司)
2012: Absorbed and merged PPCJ Co., Ltd.
2012: Established a local subsidiary in Taiwan (ASKLEP TAIWAN Inc. / 台湾阿思克瑞普生技顧問有限公司)
2012: Established a local subsidiary in South Korea (ASKLEP KOREA Inc. / 아스크랩코리아)
2013: Established the current RPS Asklep Inc. (JVC) in South Korea
2014: Split the clinical development business and incidental businesses into A2 Healthcare Corp. (newly established corporation). Concurrently transferred all shares held by the company in the said corporation, overseas local subsidiaries (China, Taiwan, South Korea), and RPS Asklep Inc. to ITOCHU Corporation.
2015: Concluded a capital and business alliance with Kyoto Constella Technologies
2015: Released "ADDIN EX," a new version of the EDC for Post-Marketing Surveillance "ADDIN"
2016: Concluded a capital and business alliance with Assemblogue Inc.
2016: Made Kyoto Constella Technologies Co., Ltd. a subsidiary
2018: Started providing "Patient Group Support Services" utilizing the "eCOQOLO" app
2018: Participated in "KBBM Inc.," a one-stop bioresource business at Kyoto University
2018: Participated in a consortium providing one-stop support for the processes of pharmaceutical companies and medical device manufacturers, from clinical development to sales

2019: Management integration of Asklep Inc. and ANTERIO Inc., which handle the healthcare sector of the INTAGE Group, to establish INTAGE Healthcare Inc.

2024: Split the CRO business from INTAGE Healthcare into ArkMS Co., Ltd. (newly established corporation). Concurrently became a wholly owned subsidiary of Alfresa Holdings Corporation.
2026: Concluded a business transfer agreement with REMEDIA Co., Ltd.
2026: Concluded a business transfer agreement with Mwis Corporation.